

# Identifying Patient Who Benefit from Chronic Opioid Therapy

Steven Stanos, DO

Medical Director, Swedish Health System

Pain Medicine & Services

Swedish Pain Services

Seattle, WA

Past President, American Academy of Pain Medicine

August 9, 2019

**DO**  
Identifying Patient Who  Benefit from Chronic Opioid Therapy

**MAY**  
Identifying Patient Who  Benefit from Chronic Opioid Therapy

Steven Stanos, DO  
Medical Director, Swedish Health System  
Pain Medicine & Services  
Swedish Pain Services  
Seattle, WA

August 9, 2019


## Disclosures

- Pfizer (consulting)
- Scilex (consulting)
- Salix (consulting)

## Overview

- Considerations around decision for opioid therapy
- Extending beyond opioid “analgesia”
- Should focus and emphasis change?
- Who is not a good candidate ?
- “Patient-centered” to the test
- Can we use current “tools” more effectively?
- Two patient stories


## Drugs Involved in U.S. Overdose Deaths 1999 to 2017



## 4<sup>th</sup> Wave: Pharmacovigilance and Pain Management Vacuum

## Opioid Therapy: Current & Future State

Therapeutic  
Options



PAST



PRESENT



FUTURE



**Why is treating pain such a challenge?**



**Repent !**

?



## “Pain”

Most discussion of pain begin with a definition, which quickly reveals its inadequacy, followed by a quasi-philosophical discussion of the mind-body problem, with the author finally opting for dualism, psychophysical parallelism or some kind of monism in which the pain experience is epiphenomenal to the ‘real’ events taking place in the tissues and nervous system.”

- *Clark and Hunt, 1971*

## FOUR CONSIDERATIONS

1. Pain Uniformity Myth
2. Negative Affect
3. Opioid Receptor: Beyond Analgesia
4. Pitfalls of Unidimensional Tools

# 1. Patient “Uniformity Myth”





## Patient “Uniformity Myth”

- Chronic pain patients are heterogeneous
- Different combinations of physical, cognitive, behavioral, and affective contributions to experience of pain
- Approaches based on patient characteristics or patient preferences
- Applying principles of patient-centered approach for opioid management should be synonymous with ANY intervention

## 2. Negative Affect




## Negative Affect

- Correlates with increased pain intensity and poorer function with LBP patients
- Cancer postoperative pain: magnitude of negative affective symptoms correlated with higher opioid doses
- NA as a stronger predictor of opioid misuse vs pain level
- NA psychopathology predicts poor outcome in chronic LBP

## Negative Affect and Diminished Opioid Analgesia & Increased Opioid Misuse

- Negative Affect: depression, anxiety catastrophizing
- CLBP study: 6.5 month prospective study
- Treatment: opioid titration phase , 4 month continuation phase
- **Results:**
  - 25% dropout rate
  - High NA group: higher daily MED vs lower pain relief
  - High NA group: greater rate of opioid misuse (39% vs 8%), and greater opioid side effects

# Factors That influence Nociceptive Inputs Affecting pain perception



## General

Analgesia

Altered mood

Decreased anxiety

Respiratory depression

Inhibition central reflexes


(-) GI motility

Cough suppression

(-) CRF, ACH

Miosis

Pruritus, nausea, vomiting



## Reinforcing Effects

Reduce anxiety

Decrease boredom


Decrease aggression

Increase self-esteem

1. Epstein S. In: *Clinical Manual Addiction Psychopharmacology*, 2005.

2. *Facing Addiction In America. Surgeon General's Report*. US Dept. HHS, 2016.

# Opioid Receptor Activity Mood, Euphoria, Reward Continuum



## 4. Unidimensional Pain Measures

### Pain as Vital Sign

- Numeric Rating Scale (NRS) (0-10)
- Visual Analog Scale (0-10)

### Multidimensional Pain Tools

- PEG<sub>1</sub>
- BPI<sub>2</sub>, SF-36 Bodily Pain, Roland Morris Disability Questionnaire
- PROMIS-PI<sub>3</sub>
- Overall Benefit of Analgesic Score (OBAS)<sub>4</sub>
- Clinically Aligned Pain Assessment Tool (CAPA)<sub>5</sub>

1. Krebs E, et al. *J Gen Intern Med.* 2009; 24:733-738.

2. Cleeland C Ryan K. *Ann Acad Med Singapore* 1994;23:129-138.

3. Amtmann D, et al. *Pain* 2010;150:173-182.

4. Lehman N, et al. *British J Anaesthesia* 2010;105:511-518.

5. Donaldson and Chapmen. 2013: Univ Utah Dept Anesthesiology.

## Use tools in a patient-centered manner or don't use them at all !



# Follow Up Visits: Objective or Metrics

WAC 246-919-880; 885; WAC 246-853-700; WAC 246-840-470

**Objectives or metrics to be used to determine treatment success if opioids are to be continued:**

- (a) Change in pain level (P)
- (b) Change in psychosocial function (E)
- (c) Change in physical function (G)
- (d) Additional indicated diagnostic evaluations or other treatments

**Pain, Enjoyment in Life, General Activity**

## PEG 3

1 What number best describes your pain on average in the past week?

0 1 2 3 4 5 6 7 8 9

No Pain

10  
Pain as bad as you can imagine

2 What number best describes how, on average, your pain interferes with your normal activities of daily life?

0 1 2 3 4 5 6 7 8 9

No Pain

10  
Pain as bad as you can imagine

3 What number best describes how, on average, your pain interferes with your ability to perform your usual activities?

0 1 2 3 4 5 6 7 8 9

No Pain

10  
Pain as bad as you can imagine

Krebs E, et al. PEG Scale Development and Validation. *J Gen Intern Med* 2009;24(6):733-8.  
Cleeland CS, Ryan K. *Ann Acad Med Singapore*. 1994;231:129-38.

## PEG 3

1 What number best describes your pain on average in the past week?

0 1 2 3 4 5 6 7 8 9 10  
No Pain Pain as bad as you can imagine

2 What number best describes how, during the past week, pain has interfered with your enjoyment of life



0 1 2 3 4 5 6 7 8 9 10  
No Pain Pain as bad as you can imagine

3 What number best describes how, during past week pain has interfered with you general activity?

0 1 2 3 4 5 6 7 8 9 10  
No Pain Pain as bad as you can imagine


Krebs E, et al. PEG Scale Development and Validation. *J Gen Intern Med* 2009;24(6):733-8.  
Cleeland CS, Ryan K. *Ann Acad Med Singapore*. 1994;231:129-38.

# Biopsychosocial Model of Pain Management




U.S. Department of Health and Human Services. Pain Management Best Practices Inter-Agency Task Force Report: Updates, Gaps, Inconsistencies, and Recommendations. Published May 9, 2019. Available at <https://www.hhs.gov/sites/default/files/pmtf-final-report-2019-05-23.pdf>. Accessed June 1, 2019.

# Best Practices for Opioid Prescribing



Washington State AMDG *Interagency Guideline on Prescribing Opioids for Pain*. 2015. Washington State Legislature. WAC



MMWR, CDC Guideline for Prescribing Opioids. March 15, 2016, Vol. 65. 1-50.



Adopted July 17, 2018

**Prescribing Opioids for Postoperative Pain**



## Recreational User



**High dose low function, psychosocial distress**




**Moderate dose, pain, & function stable**

**Low dose compliant, high risk**



**Rewarding and anxiolytic properties of opioids**

# Putting It All Together



Opioids MAY be part of a treatment plan,  
but not THE plan.

# CDC Opioid Guideline

## Determining need for opioids

- Opioids are not first-line or routine therapy for chronic pain.
- Establish and measure goals for pain and function.
- Discuss benefits and risks of opioid therapy and availability of nonopioid therapies.

## Opioid selection, dosage, and duration of therapy

- Use immediate-release opioids when starting treatment.
- Start low and go slow.
- Reassess pain and function when doses reach >50 mg of morphine equivalents a day and avoid increasing doses to >90 mg a day without justification
- Follow-up and re-evaluate risk of harm; reduce dose or taper and discontinue if needed.

## Assessing risk and addressing harm

- Evaluate risk factors for opioid-related harms.
- Check PDMP for high dosages and prescriptions from other providers.
- Use urine drug testing to identify prescribed substances and undisclosed use.
- Avoid concurrent benzodiazepine and opioid prescribing.
- Arrange treatment for OUD if needed.

# MAY Identifying Patient Who Benefit from Chronic Opioid Therapy

- 63 yr. old, rheumatoid arthritis, lumbar spondylosis, s/p L3-sacrum fusion
- Chronic renal disease, COPD, chronic prednisone
- Retired "lumbar jack"
- Oxycodone 15 mg, 1 TID, MED: 60
- GAD-7, PHQ-9 elevated
- Physical Exam:

# DON'S ASSESSMENT

## Determining need for opioids

- Opioids are not first-line or routine therapy for chronic pain.
- Establish and measure goals for pain and function.
- Discuss benefits and risks of opioid therapy and availability of nonopioid therapies.

- Patient-centered history
- Functional goals (3)
- Patient expectations
- Risk

## Pain Navigator

- PEG
- MED
- Opioid Risk Tool (ORT)
- Urine Screen
- Treatment Agreements
- Risk Stratification Tool
  - MED / ORT
  - Adjust for Medical Comorbidities (1)
  - Adjust for Medications at Greater Risk of Overdose (2)
  - Final “Management Classification”

– Low, Medium, High




 **SWEDISH**  
**Opioid Pathway: Documenting the ORT & PEG**

Epic June Wave: 6/26/18	EpicCare Ambulatory
Creation Date: June, 2018	Last modified: June, 2018

Audience: MA's, Nurses

This job aid details the steps for documenting the Opioid Risk Tool (ORT) and the Pain, Enjoyment of Life, and General Activity (PEG) forms.

How to Navigate:  
While in an encounter, the 'Pain Screening' tool can be accessed through the 'Quick Navigator' drop down

The diagram shows a list of tools under the 'PAIN' category: ORT, PEG, Opioid Mgmt, Chronic Pain Report, and Pain Synopsis. These tools are linked to two categories: 'MA/RN/LPN Rooming Sequence Tools' and 'Provider Documentation Tools'.

# Don's: Opioid Risk Tool (ORT)

Mark each box that applies		Female	Male
<b>1. Family Hx of substance abuse</b>	Alcohol	<input type="checkbox"/> 1	<input checked="" type="checkbox"/> 3
	Illegal drugs	<input type="checkbox"/> 2	<input type="checkbox"/> 3
	Prescription drugs	<input type="checkbox"/> 4	<input type="checkbox"/> 4
	<b>2. Personal Hx of substance abuse</b>		
Alcohol	<input type="checkbox"/> 3	<input checked="" type="checkbox"/> 3	
Illegal drugs	<input type="checkbox"/> 4	<input type="checkbox"/> 4	
Prescription drugs	<input type="checkbox"/> 5	<input type="checkbox"/> 5	
<b>3. Age between 16 &amp; 45 yrs</b>	<input type="checkbox"/> 1	<input type="checkbox"/> 1	
<b>4. Hx of preadolescent sexual abuse</b>	<input type="checkbox"/> 3	<input type="checkbox"/> 0	
<b>5. Psychologic disease</b>	ADD, OCD, bipolar, schizophrenia	<input type="checkbox"/> 2	<input type="checkbox"/> 2
	Depression	<input type="checkbox"/> 1	<input type="checkbox"/> 1

**Administer**

On initial visit

---

Prior to opioid therapy

**Scoring (RISK)**

**0-3: low**

---

**4-7: moderate**

---

**≥8: high**

**Scoring Totals: 6, moderate RISK**

# Assessment and Risk Stratify

## Medications:

Oxycodone 15 mg Q 4-5 hrs (60 MED)

Gabapentin 200 mg QHS

Amitriptyline 25 mg QHS

Robaxin 750 mg PRN

## Screening

PHQ-9

GAD-7

Opioid Risk Tool: moderate

## Monitoring

Urine monitoring

PMP: consistent w/prescribers

## Management Classification

Step #1 Adjustment		
<b>MED (Morphine Equiv. Dose)</b>	<b>Opioid Risk Tool (ORT)</b>	<b>Consider higher of the two categories</b>
Low: < 50	Low risk = neutral risk	<b>MED</b> <b>ORT</b> <b>Step 1 Adjustment</b>
Medium: 50-90	Moderate risk = at least "medium" risk	Low    Medium    Medium
High: > 90	High risk = at least "high" risk	Medium    Low    Medium
		High    Low    High

Step #2 Adjustment	Medical comorbidities and concurrent meds (add "A" and "B")
<b>A. Medical comorbidities (1 point per)</b> impaired respiratory function, COPD, CHF, untreated sleep apnea, high fall risk, altered drug metabolism, advanced age/frail, impaired renal or hepatic dysfunction, unstable psychiatric condition (i.e., depression, anxiety), other Subtotal A: _____	<b>B. Concurrent high risk co-prescriptions: (1 point per)</b> Benzodiazepines, barbiturates, carisoprodol, non-benzodiazepine hypnotics, stimulant medications, other Subtotal B: _____
Add subtotals "A" and "B" for total adjustment score: _____ If > 2 points = Consider grade <b>UP</b> If 1 point = Maintain classification If 0 points = Consider grade <b>DOWN</b>	<b>Final "management classification" score</b> "Low" "Medium" "High"

- Use the management classification score for ongoing monitoring.
- Risk factors may change over time. Reassess regularly.
- Methadone MED classification is limited by unique qualities of the drug.

## PEG 3

1 What number best describes your pain on average in the past week?

0 1 2 3 4 5 6 7 8 9 10  
No Pain Pain as bad as you can imagine

2 What number best describes how, during the past week, pain has interfered with your enjoyment of life

0 1 2 3 4 5 6 7 8 9 10  
No Pain Pain as bad as you can imagine

3 What number best describes how, during past week pain has interfered with you general activity?

0 1 2 3 4 5 6 7 8 9 10  
No Pain Pain as bad as you can imagine

## Ongoing Patient-Centered (PC) Assessment

PEG

Analgesic Response

Mood

Sleep

Patient Goals & Expectations

Daily Routine

Compliance Monitoring

Clinicians are pretty good at identifying  
when a patient “didn’t do well” on  
opioids.

But many times it’s too late.

## Opioid Therapy: Risk Factors

### **Aberrant behaviors**

- Family and personal history of substance misuse, abuse
- Psychiatric comorbidity
- Age
- Trauma

### **Poor analgesic response**

- Psychosocial, negative affect
- Genetic characteristics
- Incomplete assessment
- Lack of knowledge
- Incongruent expectations
- Diversion

# Tapering Considerations

WAC 246-919-950

- **Consider tapering or referral for substance abuse disorder evaluation if:**
  - Patient requests;
  - **Patient experiences a deterioration in function or pain;**
  - Patient is noncompliant with the written agreement;
  - Other treatment modalities are indicated;
  - There is evidence of misuse, abuse, substance use disorder or diversion
  - Patient experiences a severe adverse event or overdose;
  - **Patient is receiving escalation in opioid dosage with no improvement in pain or function.**

# DO Identifying Patient Who Benefit from Chronic Opioid Therapy

- 71 yr old retired nurse
- Severe low back and leg pain
- Spinal stenosis, kyphoscoliosis
- Myofascial pain, obesity
- Rheumatoid arthritis
- Depression
- “failed multiple opioids”

## Interdisciplinary Approach: 4 week Program

		<b>Monday</b>	<b>Wednesday</b>	<b>Friday</b>
<b>Treatment Team</b> > Pain medicine > Physical therapy (PT) > Occupational therapy (OT) > Relaxation training > Pain Psychology > Nursing Education	Noon	<b>Nursing Lecture</b>	<b>Group Stretching Class</b>	<b>Nursing Lecture</b>
	1:00	<b>Physical Therapy</b>	<b>Physical Therapy Group</b>	<b>Physical Therapy</b>
	2:00	<b>OT</b>	<b>Medical Visit</b>	<b>Occupational Therapy</b>
	3:00	<b>Psychology</b>	<b>Psychology Group</b>	<b>Psychology</b>
	4:00	<b>Relaxation Training</b>	<b>Relaxation Group</b>	<b>Relaxation Training</b>
	5:00	<b>Team Conference:</b> Physician, Nurse, PT, OT, Psych, Relax Therapist		




**So, who does benefit?**

**“ Repent ”**

**Change your mind**

**Change your thinking**



# Opioid Therapy

- Future state of integrating opioid therapy as an option is here.
- Pain uniformity myth, negative affect . . .
- Analgesia: mood, euphoria, reward continuum
- Multidimensional tools and patient-centered approach.
- Biopsychosocial assessment and getting back to the basics.
- Selection of opioids as part of treatment plan, not THE plan.
- Moving beyond the 5<sup>th</sup> vital sign to a “PC Assessment”
- Use tools and guidelines.



Thank you! [steven.stanos@swedish.org](mailto:steven.stanos@swedish.org)

